

Technology Appraisal Committee A Interests Register

Topic: Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]

Publication Date: 06 August 2025

| Name | Role with NICE | Type of interest | Description of interest | Interest Declared | Comments |
|---------------------------|-----------------|--------------------|--|-------------------|---|
| Professor Fiona Blackhall | Clinical Expert | Direct - Financial | Speaker fees and Honoraria for Steering Committee and Advisory Board Roles for Amgen – past four years | 08/10/2024 | It was agreed that Professor Blacknell's declaration would not prevent her from providing expert advice to the committee. |
| Dr Yvonne Summers | Clinical Expert | Direct - Financial | <p>Dr Summers received honoraria for advisory work and speaker fees from most of the pharmaceutical companies working in drug development in lung cancer:</p> <ul style="list-style-type: none"> • Support to attend educational conferences from Roche, Takeda • Advisory Board for Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, EQRX, Lilly, MSD, Roche, Takeda, Lilly, Pfizer, J&J | 08/10/2024 | It was agreed that Dr Summers' declaration would not prevent her from providing expert advice to the committee. |

| | | | | | |
|-----------------|------------|--------------------------------|--|------------|---|
| | | | <ul style="list-style-type: none"> • Speaker Fees from Amgen, Astra-Zeneca, BMS, Lilly, Sanofi, Takeda | | |
| Patrick de Barr | TAC Member | Direct – Financial Interests | Patrick participated in ACM 1 for this topic in October 2024. In November he started working at GSK who have an asset in development moving to phase 3 in Extensive Stage Small Cell Lung Carcinoma - this is a potential comparator in the future and a conflict of interest. | 13/05/2025 | It was agreed that Patrick's declaration would prevent him from participating in discussions on this appraisal. |
| Dominic Pivonka | TAC Member | Indirect – Financial Interests | Dominic's employer (AbbVie) has a treatment being evaluated for small-cell lung cancer in phase 1 | 20/05/2025 | It was agreed that Dominic's declaration would not prevent him from participating in discussions on this appraisal. |
| Hugo Pedder | TAC Member | | I have received payment for statistical consultancy work done on behalf of Baxter Healthcare. The work was unrelated to the technology or indication under current consideration. | 15/05/2025 | It was agreed that Hugo's declaration would not prevent him from participating in discussions on this appraisal. |
| Prithwiraj Das | TAC Member | | I work in life sciences, including pharmaceutical | 16/05/2025 | It was agreed that Prithwiraj's |

| | | | | | |
|------------------|------------|--------------------------------|---|------------|---|
| | | | market access, as Founding Director of G2PR Ltd. I have not worked on these products/indications in the last 12+ months. | | declaration would not prevent him from participating in discussions on this appraisal. |
| Becky Pennington | TAC Member | Indirect – Financial Interests | Becky is in the process of agreeing to advise Amgen on a project in a different disease area: IgG4-RD. It will be an advisory board in mid-October. The drug she is working on is not tarlatamab. | 26/09/2024 | It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal. |